What makes SKYTROFA® different?

SKYTROFA is the first and only FDA-approved once-weekly treatment for pediatric GHD that delivers somatropin, which is used in daily growth hormone therapies

Hero Image
Calendar Icon

More injection-free days with once-weekly dosing compared with daily therapies

Not Refridgerated Icon

Convenient storage with no required refrigeration for up to 6 months* and preservative free

Icon of arrows extending outward in all directions

Higher growth rate after 1 year in a clinical trial compared with a daily somatropin therapy

Check Icon

Based on clinical data, pediatric patients treated with daily somatropin may be switched to SKYTROFA

* Store SKYTROFA in the original package to protect from light. Do not freeze. SKYTROFA can be stored at room temperature (not to exceed 86°F [30°C]) for up to 6 months. Alternatively, SKYTROFA can be stored under refrigeration at 36°F to 46°F (2°C to 8°C) until the expiration date. If refrigerated, keep at room temperature for 15 minutes before use. Do not use SKYTROFA beyond the expiration date or 6 months after the date it was first removed from refrigeration (whichever is earlier).

In a clinical trial that compared once-weekly SKYTROFA with a daily somatropin in 161 children with pediatric GHD who previously had not been on treatment. The primary endpoint from the clinical trial was measuring annualized height velocity (AHV) at 52 weeks. AHV at 52 weeks was 11.2 cm/year for SKYTROFA versus 10.3 cm/year for a daily somatropin.

SKYTROFA was studied in a 26-week clinical trial investigating the safety, tolerability, and efficacy of SKYTROFA administered once weekly in children with pediatric GHD. The trial included 3 children who previously had not been on treatment and 143 children previously treated with daily growth hormone therapies for ≤ 130 weeks. Safety and tolerability were the primary endpoints.

Boy playing the drumbs

Learn more about the established safety profile of SKYTROFA

Safety information

Explore co-pay assistance for eligible patients through the Ascendis Signature Access Program™ (A·S·A·P).